An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer

Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is commonly used in inoperable patients with early‐stage non‐small lung cancer (NSCLC). This treatment has good outcomes and low toxicity in peripherally located tumors. However, in lesions which are loca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarębska, Izabela, Harat, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542466/
https://www.ncbi.nlm.nih.gov/pubmed/37691151
http://dx.doi.org/10.1111/1759-7714.15071
_version_ 1785114100447051776
author Zarębska, Izabela
Harat, Maciej
author_facet Zarębska, Izabela
Harat, Maciej
author_sort Zarębska, Izabela
collection PubMed
description Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is commonly used in inoperable patients with early‐stage non‐small lung cancer (NSCLC). This treatment has good outcomes and low toxicity in peripherally located tumors. However, in lesions which are located close to structures such as the bronchial tree or mediastinum the risk of severe toxicity increases. This review summarizes the evidence of dose‐fractionation in SBRT of NSCLC patients in various locations.
format Online
Article
Text
id pubmed-10542466
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-105424662023-10-03 An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer Zarębska, Izabela Harat, Maciej Thorac Cancer Reviews Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is commonly used in inoperable patients with early‐stage non‐small lung cancer (NSCLC). This treatment has good outcomes and low toxicity in peripherally located tumors. However, in lesions which are located close to structures such as the bronchial tree or mediastinum the risk of severe toxicity increases. This review summarizes the evidence of dose‐fractionation in SBRT of NSCLC patients in various locations. John Wiley & Sons Australia, Ltd 2023-09-10 /pmc/articles/PMC10542466/ /pubmed/37691151 http://dx.doi.org/10.1111/1759-7714.15071 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Zarębska, Izabela
Harat, Maciej
An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title_full An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title_fullStr An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title_full_unstemmed An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title_short An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
title_sort optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542466/
https://www.ncbi.nlm.nih.gov/pubmed/37691151
http://dx.doi.org/10.1111/1759-7714.15071
work_keys_str_mv AT zarebskaizabela anoptimaldosefractionationforstereotacticbodyradiotherapyinperipherallycentrallyandultracentrallylocatedearlystagenonsmalllungcancer
AT haratmaciej anoptimaldosefractionationforstereotacticbodyradiotherapyinperipherallycentrallyandultracentrallylocatedearlystagenonsmalllungcancer
AT zarebskaizabela optimaldosefractionationforstereotacticbodyradiotherapyinperipherallycentrallyandultracentrallylocatedearlystagenonsmalllungcancer
AT haratmaciej optimaldosefractionationforstereotacticbodyradiotherapyinperipherallycentrallyandultracentrallylocatedearlystagenonsmalllungcancer

Ejemplares similares